Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by State Street Corp

State Street Corp lowered its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 50.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 704,712 shares of the company’s stock after selling 713,235 shares during the period. State Street Corp owned approximately 0.98% of Kiniksa Pharmaceuticals worth $17,611,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in KNSA. Braidwell LP lifted its position in Kiniksa Pharmaceuticals by 40.6% during the 3rd quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after acquiring an additional 836,210 shares in the last quarter. Rubric Capital Management LP lifted its position in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after purchasing an additional 108,102 shares during the period. FMR LLC grew its holdings in Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after purchasing an additional 694,928 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of analyst reports. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $36.60.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 27,092 shares of company stock valued at $673,039. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ KNSA opened at $19.94 on Wednesday. The stock’s 50 day moving average price is $22.52 and its two-hundred day moving average price is $23.16. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a market capitalization of $1.44 billion, a P/E ratio of -142.42 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue was up 67.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.20) earnings per share. On average, analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.